Careteq Maintains ASX Listing Post-EHS Divestment, Focuses on Growth of HMR Referrals Marketplace

ASX Confirms Ongoing Quotation Following Strategic Restructuring

Careteq Limited has received formal confirmation from the Australian Securities Exchange that its securities will remain listed after divesting its Embedded Health Solutions subsidiary. This milestone resolves prior regulatory uncertainties related to the divestment. The ASX’s decision followed consultations regarding Careteq’s operational plans, strategic goals, and intended use of funds post-EHS disposal, confirming the company’s sufficient operations and financial health to justify continued quotation.

This approval removes a significant regulatory barrier, allowing Careteq to confidently implement its renewed business strategy. It affirms that the divestment, although a major portfolio change, does not impair Careteq’s capability to operate as a public company. The ASX’s endorsement indicates satisfaction with the company’s strategic direction and the viability of HMR Referrals as a standalone business meeting listing requirements.

HMR Referrals Marketplace: Core Business After Divestment

Post-divestment, HMR Referrals stands as Careteq’s sole operating business. This SaaS two-sided marketplace connects general practitioners with credentialed pharmacists to facilitate Home Medicines Reviews (HMRs), a government-subsidised service reimbursed under Medicare Benefits Schedule Item 900. This focus situates Careteq within a defined regulatory and reimbursement framework, limiting exposure to market volatility and establishing revenue parameters linked to government health policy.

The HMR Referrals network has scaled significantly, encompassing over 500 accredited pharmacists, approximately 80 GP clinics, and 400 GPs nationwide. This extensive network creates a competitive advantage, as marketplace value grows with increased participants on both sides. The network’s size reflects meaningful provider adoption and a strong presence in targeted regions, supporting sustainable service delivery.

March Quarter Results: Positive Cash Flow and Revenue Growth

For the March quarter, Careteq reported customer receipts of $2.192 million, up from $2.098 million in the December quarter. This sequential growth occurred amid the operational transition involving the EHS divestment and capital raising, indicating sustained demand for HMR Referrals services despite restructuring.

The company achieved positive net operating cash flow of $14,000 in the March quarter, a notable improvement from a $95,000 outflow in the prior quarter. This shift signals a balance between revenue and operating expenses. Careteq plans to provide further updates on June quarter performance in its upcoming Q4-FY26 Activities Report and Appendix 4C cash flow statement, offering investors greater insight into post-restructuring progress.

12-Month Strategic Focus: Network Expansion and Clinic Activation

Careteq’s strategic priorities over the next year include deepening network engagement by expanding accredited pharmacist and GP clinic participation in key regions. The company also aims to integrate its platform with leading practice management systems to streamline provider adoption and enhance platform retention through workflow embedding.

Another priority is the rollout of a standardised clinic activation programme designed to convert under-utilised government HMR capacity into increased referral volumes. This approach targets unlocking latent demand within existing clinics without requiring proportional network expansion. Additionally, Careteq will explore adjacent healthcare programs, including potential extensions of the HMR Referrals marketplace into complementary community pharmacy initiatives leveraging current infrastructure.

Artificial Intelligence Strategy and Strategic Growth Evaluation

Careteq has indicated plans to develop an artificial intelligence strategy as part of its long-term growth objectives. While specifics and timelines remain undisclosed, the company is actively monitoring healthcare technology trends for opportunities to accelerate growth and AI integration. Potential paths include capability partnerships, technology collaborations, and strategic acquisitions aligned with these goals.

The company emphasises a disciplined evaluation framework, ensuring complementary opportunities align with long-term shareholder value creation. This selective approach suggests Careteq aims to avoid dilutive or off-strategy deals. The focus on AI highlights its potential as a differentiator within the healthcare services technology sector, though implementation details are yet to be announced.

Capital Raising Completion and Fund Allocation

During the March quarter, Careteq completed a two-tranche capital raise. Combined with proceeds from the EHS divestment, these funds form the company’s operational capital. Although specific allocation figures are referenced but not detailed in the announcement, the proposed use of funds supports strategic priorities such as clinic activation, pharmacist recruitment, and sector engagement. The phased capital deployment allows management to monitor returns and adjust resource allocation accordingly.

The Board confirmed that current funding is adequate to support planned activities and expenditures over the next 12 months. Careteq commits to reporting progress against the use of funds in quarterly activity reports, enhancing transparency and investor confidence in capital management.

Healthcare Market Context: Medicare Benefits Schedule and Home Medicines Reviews

Careteq operates within the Australian government-subsidised healthcare market, specifically under Medicare Benefits Schedule Item 900, which governs reimbursement for Home Medicines Reviews. This framework presents both constraints and opportunities: revenue depends on government funding and policy continuity, yet the defined reimbursement provides stable demand independent of private payer dynamics.

The home medicines review market is distinct from consumer-driven telehealth or direct-to-consumer health tech sectors, offering revenue certainty but limiting market size to government-allocated volumes. Careteq’s focus on converting under-utilised HMR capacity suggests significant growth potential exists within the current reimbursement system. Exploration of adjacent community pharmacy programs may further expand the addressable market using existing provider networks.

Competitive Advantage and Network Effects in Home Medicines Review Services

The HMR Referrals platform benefits from network effects, connecting over 500 accredited pharmacists and 400 GPs across approximately 80 clinics nationwide. This scale fosters switching costs and a competitive moat, as pharmacists gain access to more referrals and GPs connect with a broader pharmacist base, creating mutual dependencies that deter competitor entry.

Careteq’s strategy to deepen engagement within targeted regions rather than broad geographic expansion reflects a focus on optimising network density where unmet demand exists. Integration with leading practice management systems further embeds the platform into provider workflows, enhancing retention and competitive positioning beyond network size alone.

Financial Sustainability and Path to Profitability

The shift to positive operating cash flow in the March quarter marks a key operational achievement, indicating progress toward self-sustaining business operations. Generating $14,000 in net operating cash flow on $2.192 million in customer receipts demonstrates improved unit economics and operational efficiency despite concurrent divestment and capital raising activities.

The Board’s confidence in funding sufficiency assumes successful growth in customer receipts and controlled operating expenses. Effective execution of clinic activation and pharmacist recruitment initiatives could accelerate profitability, while cost overruns or slower growth might necessitate additional capital. The staged capital deployment approach provides flexibility to adjust spending based on performance.

Risks and Execution Challenges

Careteq’s strategic success depends on executing network expansion, clinic activation, and evaluation of complementary opportunities concurrently. Execution risks include potential underperformance in referral volume growth or higher-than-expected recruitment costs, which could delay profitability and require further funding.

Interest in acquisitions and partnerships introduces integration risks, especially given the company’s modestly positive cash flow and limited capital. Additionally, regulatory risks persist due to reliance on government inclusion of HMR services within the Medicare Benefits Schedule. Changes in policy, reimbursement, or program design could materially affect market size and revenue, independent of operational execution. The company has not disclosed the proportion of revenue derived specifically from MBS-funded HMR services versus other sources.